References
1 Wild S et al. (2004) Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 27: 1047–1053 2 King H et al. (1998) Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 21: 1414–1431 3 Klein R et al. (1996) The incidence of hypertension in insulin-dependent diabetes. Arch Intern Med 156: 622–627 4 Wannamethee SG et al. (2005) Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. Arch Intern Med 165: 2644–2650 5 Adler AI et al. (2000) Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412–419 6 Najarian RM et al. (2006) Metabolic syndrome compared with type 2 diabetes mellitus as a risk factor for stroke: the Framingham Offspring Study. Arch Intern Med 166: 106–111 7 Chobanian AV et al. (2003) Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42: 1206–1252 8 No authors listed (1994) National High Blood Pressure Education Program Working Group report on hypertension in diabetes. Hypertension 23: 145–158 9 Makrilakis K and Bakris G (1998) Diabetic hypertensive patients: improving their prognosis. J Cardiovasc Pharmacol 31 (Suppl 2): S34–S40 10 Arauz-Pacheco C et al. (2003) Treatment of hypertension in adults with diabetes. Diabetes Care 26 (Suppl 1): S80–S82 11 Cooper ME and Johnston CI (2000) Optimizing treatment of hypertension in patients with diabetes. JAMA 283: 3177–31179 12 No authors listed (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317: 703–713 13 No authors listed (1998) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group BMJ 317: 713–720 14 No authors listed (2000) Effects ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus; results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation (HOPE) Investigators. Lancet 355: 253–259